Venture
Recode Therapeutics, Inc.
Latest Form D 2025-10-23- CIK 1693764
- State CA
- Biotechnology
- 4 Form D offerings since 2017-01-05
- Total sold
- $319M
- across 4 offerings
- Rounds
- 4
- Form D offerings since 2017-01-05
- Latest round
- $29.4M
- 2025-10-23 · 021-561915
- Investors
- 26
- on the latest round
Connected
named in its Form D filingsOfferings · since 2017-01-054 Form D offeringsExemptions506(b)People · Item 3Shehnaaz Suliman + 11 moreInvestors · dashboard4 inferred investors
Recode Therapeutics, Inc.CIK 1693764
Round timeline
amount sold · by first filed2025-10-23 · $29.4M
- 2017-01-05$2M021-277752
- 2020-03-20$27.5M021-363315
- 2021-10-25$260M021-418416
- 2025-10-23$29.4M021-561915
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($260M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-561915 | First filed2025-10-23 | Latest2025-10-23 | Sought$29.4M | Sold$29.4M | Investors26 | Exemptions506(b) |
| 021-418416 | First filed2021-10-25 | Latest2023-09-28 | Sought$290M | Sold$260M | Investors28 | Exemptions506(b) |
| 021-363315 | First filed2020-03-20 | Latest2020-03-20 | Sought$80M | Sold$27.5M | Investors9 | Exemptions506(b) |
| 021-277752 | First filed2017-01-05 | Latest2019-02-08 | Sought$3M | Sold$2M | Investors1 | Exemptions506(b) |
Who backs Recode Therapeutics, Inc. — 4 inferred investors — and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-10-23
| Name | Relationship |
|---|---|
| Shehnaaz Suliman | RelationshipExecutive Officer, Director |
| Peter A. Thompson | RelationshipDirector |
| Helen S. Kim | RelationshipDirector |
| Edward Hurwitz | RelationshipDirector |
| Rana Al-Hallaq | RelationshipDirector |
| Rakhshita Dhar | RelationshipDirector |
| Alan Colowick | RelationshipDirector |
| Patricia Millican | RelationshipDirector |
| Dean Mitchell | RelationshipDirector |
| Inai Park | RelationshipDirector |
| Basheer Zada | RelationshipDirector |
| David Lockhart | RelationshipExecutive Officer |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2017-01-05
- Latest filing
- 2025-10-23
Who backs Recode Therapeutics, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗